Grant Life Sciences

U.S. Patent and Trademark Office finds HPV-related application is 'patentable'

Published in Pharma Law Weekly, December 28th, 2004

Grant Life Sciences (GLIF) has received notice from the U.S. Patent and Trademark Office, acting as the International Preliminary Examining Authority on behalf of the World Intellectual Property Organization, that one of the company's patent applications meets the criteria for patentability.

Patentability means it possesses novelty, inventive step, and industrial applicability compared to known prior art.

The exclusively licensed international patent, "Peptides from the E2, E6 and E7 Proteins of Human Papillomaviruses 16 and 18 for Detecting and/or Diagnosing Cervical and Other Cancers," is part of a comprehensive intellectual property patent...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2004-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry